[go: up one dir, main page]

BRPI9711437B8 - derivados de glp-1 - Google Patents

derivados de glp-1

Info

Publication number
BRPI9711437B8
BRPI9711437B8 BRPI9711437A BR9711437A BRPI9711437B8 BR PI9711437 B8 BRPI9711437 B8 BR PI9711437B8 BR PI9711437 A BRPI9711437 A BR PI9711437A BR 9711437 A BR9711437 A BR 9711437A BR PI9711437 B8 BRPI9711437 B8 BR PI9711437B8
Authority
BR
Brazil
Prior art keywords
glp
derivatives
analogues
pharmacological properties
lipophilic substituent
Prior art date
Application number
BRPI9711437A
Other languages
English (en)
Other versions
BRPI9711437B1 (pt
BR9711437A (pt
Inventor
Bjerre Knudsen Liselotte
Franklin Nielsen Per
Olaf Huusfeldt Per
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27221005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9711437(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9711437A publication Critical patent/BR9711437A/pt
Publication of BRPI9711437B1 publication Critical patent/BRPI9711437B1/pt
Publication of BRPI9711437B8 publication Critical patent/BRPI9711437B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)

Abstract

derivados de glp-1 e seus análogos tendo um substituinte lipofílico possuem propriedades farmacólogicas interessants, em particular têm um perfil de ação mais protracted do que glp-1 (7-37).
BRPI9711437A 1996-08-30 1997-08-22 derivados de glp-1 BRPI9711437B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK93196 1996-08-30
DK125996 1996-11-08
DK147096 1996-12-20
PCT/DK1997/000340 WO1998008871A1 (en) 1996-08-30 1997-08-22 Glp-1 derivatives

Publications (3)

Publication Number Publication Date
BR9711437A BR9711437A (pt) 2000-01-18
BRPI9711437B1 BRPI9711437B1 (pt) 2017-05-16
BRPI9711437B8 true BRPI9711437B8 (pt) 2021-05-25

Family

ID=27221005

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9711437A BRPI9711437B8 (pt) 1996-08-30 1997-08-22 derivados de glp-1

Country Status (21)

Country Link
EP (2) EP1826216A1 (pt)
JP (3) JP3149958B2 (pt)
KR (1) KR100556067B1 (pt)
CN (1) CN1271086C (pt)
AT (1) ATE356830T1 (pt)
BR (1) BRPI9711437B8 (pt)
CA (2) CA2468374C (pt)
CZ (1) CZ300837B6 (pt)
DE (3) DE69737479T4 (pt)
DK (1) DK0944648T3 (pt)
ES (1) ES2283025T3 (pt)
FR (1) FR09C0054I2 (pt)
HU (1) HU227021B1 (pt)
IL (3) IL128332A0 (pt)
NL (1) NL300422I2 (pt)
NO (3) NO325273B1 (pt)
PL (1) PL192359B1 (pt)
PT (1) PT944648E (pt)
RU (1) RU2214419C2 (pt)
UA (1) UA72181C2 (pt)
WO (1) WO1998008871A1 (pt)

Families Citing this family (509)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
KR100556067B1 (ko) * 1996-08-30 2006-03-07 노보 노르디스크 에이/에스 지엘피 - 1 유도체
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1840134B1 (en) * 1998-02-27 2016-04-13 Novo Nordisk A/S GLP-1 derivatives
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69916811T2 (de) * 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE69911975T2 (de) 1998-07-31 2004-09-09 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CZ2001690A3 (cs) * 1998-08-28 2002-04-17 Eli Lilly And Company Způsob podávání inzulinotropních peptidů
CN1317967A (zh) 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CZ295890B6 (cs) * 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou pozici 8 a D-arginin na pozici 36, jejich použití a farmaceutické prostředky je obsahující
PL189664B1 (pl) * 1998-12-07 2005-09-30 Sod Conseils Rech Applic Nowy analog GLP-1, kompozycja farmaceutyczna go zawierająca oraz zastosowanie nowego analogu GLP-1
KR100458748B1 (ko) 1998-12-07 2004-12-03 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Ｇｌｐ-1 유사체
PT1140145E (pt) * 1999-01-14 2005-11-30 Amylin Pharmaceuticals Inc Formulacoes novas de agonistas de exendina e metodos para a sua administracao
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
WO2000055203A1 (en) * 1999-03-15 2000-09-21 Novo Nordisk A/S Ion exchange chromatographic separation of glp-1 and related peptides
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
JP4949557B2 (ja) * 1999-03-17 2012-06-13 ノヴォ ノルディスク アー／エス ペプチドのアシル化方法及び新規アシル化剤
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
WO2000066629A1 (en) * 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
AU1269501A (en) * 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
EP1634605A3 (en) 2000-03-08 2006-10-11 Novo Nordisk A/S treatment of dyslipidemia in a patient having type 2 diabetes
DE10013895A1 (de) 2000-03-21 2001-10-04 Dmc2 Degussa Metals Catalysts Cerdec Ag Verfahren zur katalytischen Umsetzung von Kohlenmonoxid in einem Wasserstoff enthaltenden Gasgemisch
CN1454214A (zh) * 2000-08-02 2003-11-05 赛莱技术公司 具有增高功效的修饰生物肽
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
IL156548A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DE50111751D1 (de) 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
EP1949908A1 (en) 2001-03-07 2008-07-30 Novo Nordisk A/S Combined use of derivatives of GLP-1 analogs and PPAR ligands
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE10142660A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
EP1385867B1 (en) * 2001-05-02 2006-08-30 Novo Nordisk A/S Preparation of bile acids
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
ATE382057T1 (de) * 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
WO2003018024A1 (de) 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
DE10142668A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142722A1 (de) 2001-08-31 2003-03-27 Aventis Pharma Deutschland GmbH, 65929 Frankfurt C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10142662B4 (de) 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142665B4 (de) 2001-08-31 2004-05-06 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-one und ihre Derivate
DE10142666A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
DE10142661B4 (de) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
DE10142667B4 (de) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE50208960D1 (de) 2001-08-31 2007-01-25 Sanofi Aventis Deutschland Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
DE10142659A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
HRP20040343A2 (en) 2001-10-18 2005-08-31 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
JP4282485B2 (ja) * 2002-01-08 2009-06-24 イーライ リリー アンド カンパニー 伸長グルカゴン様ペプチド−１アナログ
EP1474163A2 (en) * 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
JP4417113B2 (ja) 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
US7223796B2 (en) 2002-04-11 2007-05-29 Sanofi-Aventis Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en) 2002-06-07 2006-05-23 Aventis Pharma Deutschland Gmbh N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
ATE432289T1 (de) * 2002-07-04 2009-06-15 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7262220B2 (en) 2002-07-11 2007-08-28 Sanofi-Aventis Deutschland Gmbh Urea- and urethane-substituted acylureas, process for their preparation and their use
HRP20050022A2 (en) 2002-07-12 2006-03-31 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
CA2500021A1 (en) 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
BR0314289B8 (pt) * 2002-09-25 2021-07-27 Novo Nordisk As método para produzir um peptídeo n-acilado
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
US20040157922A1 (en) 2002-10-04 2004-08-12 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
US7208504B2 (en) 2002-10-12 2007-04-24 Sanofi-Aventis Deutschland Gmbh Bicyclic inhibitors of hormone sensitive lipase
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2509755A1 (en) 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20040242583A1 (en) 2003-01-20 2004-12-02 Aventis Pharma Deutschland Gmbh Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
ATE502665T1 (de) 2003-02-04 2011-04-15 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
US7652007B2 (en) 2003-02-13 2010-01-26 Sanofi-Aventis Deutschland Gmbh Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
US7390814B2 (en) 2003-02-13 2008-06-24 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
JP4548335B2 (ja) 2003-03-07 2010-09-22 味の素株式会社 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
PT1605897E (pt) 2003-03-19 2012-09-10 Lilly Co Eli Compostos de glp-1 ligado a polietilenoglicol
WO2004087910A1 (ja) * 2003-03-28 2004-10-14 National Institute Of Agrobiological Sciences 組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2004094823A2 (en) 2003-04-23 2004-11-04 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
AU2004266757A1 (en) 2003-08-21 2005-03-03 Novo Nordisk A/S Separation of polypeptides comprising a racemized amino acid
WO2005023291A2 (en) * 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
RU2401276C2 (ru) * 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
EP1684793B1 (en) * 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
SI3300721T2 (sl) 2003-11-20 2025-05-30 Novo Nordisk A/S Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
EP1711523B1 (en) * 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
EP1694278A4 (en) 2003-12-16 2009-08-12 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
EP1704165B1 (en) 2003-12-18 2010-03-17 Novo Nordisk A/S Glp-1 compounds
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
CA2552526A1 (en) * 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
ES2397241T3 (es) 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en) 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
KR100564618B1 (ko) 2004-03-11 2006-03-28 삼성전자주식회사 디스크 드라이브의 층간 탐색 방법
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
ES2458991T5 (en) 2004-11-12 2025-10-14 Novo Nordisk As Stable formulations of insulinoptropic peptides
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
ES2428510T3 (es) 2005-02-02 2013-11-08 Novo Nordisk A/S Derivados de insulina
EP1846447B1 (en) 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
US8840586B2 (en) 2006-08-23 2014-09-23 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US20080097291A1 (en) 2006-08-23 2008-04-24 Hanson Ian B Infusion pumps and methods and delivery devices and methods with same
US8512288B2 (en) 2006-08-23 2013-08-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8137314B2 (en) 2006-08-23 2012-03-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with compressible or curved reservoir or conduit
US7905868B2 (en) 2006-08-23 2011-03-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8277415B2 (en) 2006-08-23 2012-10-02 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US7569050B2 (en) 2005-05-06 2009-08-04 Medtronic Minimed, Inc. Infusion device and method with drive device in infusion device and method with drive device in separable durable housing portion
JPWO2006126673A1 (ja) * 2005-05-27 2008-12-25 第一三共株式会社 組み合わせによる糖尿病治療薬
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
ES2397289T3 (es) * 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
BRPI0618649A2 (pt) 2005-11-17 2011-09-06 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
ES2397712T3 (es) 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
US12151080B2 (en) 2006-02-09 2024-11-26 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US11478623B2 (en) 2006-02-09 2022-10-25 Deka Products Limited Partnership Infusion pump assembly
US11364335B2 (en) 2006-02-09 2022-06-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11027058B2 (en) 2006-02-09 2021-06-08 Deka Products Limited Partnership Infusion pump assembly
US12370305B2 (en) 2006-02-09 2025-07-29 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
AU2007212269B2 (en) 2006-02-09 2013-03-28 Deka Products Limited Partnership Fluid delivery systems and methods
US11318249B2 (en) 2006-02-09 2022-05-03 Deka Products Limited Partnership Infusion pump assembly
US12274857B2 (en) 2006-02-09 2025-04-15 Deka Products Limited Partnership Method and system for shape-memory alloy wire control
US12070574B2 (en) 2006-02-09 2024-08-27 Deka Products Limited Partnership Apparatus, systems and methods for an infusion pump assembly
US11497846B2 (en) 2006-02-09 2022-11-15 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
SI2383271T1 (sl) 2006-03-13 2013-10-30 Kyorin Pharmaceutical Co., Ltd. Aminokinoloni kot inhibitorji gsk-3
JP5312054B2 (ja) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー／エス アミリンとインスリンの混合物
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
ES2566058T3 (es) 2006-03-30 2016-04-08 Valeritas, Inc. Dispositivo de suministro de fluidos de múltiples cartuchos
WO2007127704A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
ATE538116T1 (de) 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008008363A1 (en) 2006-07-11 2008-01-17 Qps, Llc Pharmaceutical compositions for sustained release delivery of peptides
WO2008011446A2 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
US7794434B2 (en) 2006-08-23 2010-09-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7736338B2 (en) 2006-08-23 2010-06-15 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US7811262B2 (en) 2006-08-23 2010-10-12 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7828764B2 (en) 2006-08-23 2010-11-09 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
BRPI0716134A2 (pt) 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
US8022066B2 (en) 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2008098246A1 (en) 2007-02-09 2008-08-14 Deka Products Limited Partnership Automated insertion assembly
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
US8323250B2 (en) 2007-04-30 2012-12-04 Medtronic Minimed, Inc. Adhesive patch systems and methods
US8613725B2 (en) 2007-04-30 2013-12-24 Medtronic Minimed, Inc. Reservoir systems and methods
US7959715B2 (en) 2007-04-30 2011-06-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US8434528B2 (en) 2007-04-30 2013-05-07 Medtronic Minimed, Inc. Systems and methods for reservoir filling
US8597243B2 (en) 2007-04-30 2013-12-03 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
JP5102350B2 (ja) 2007-04-30 2012-12-19 メドトロニック ミニメド インコーポレイテッド リザーバ充填／気泡管理／注入媒体送給システムおよび該システムを用いる方法
US7963954B2 (en) 2007-04-30 2011-06-21 Medtronic Minimed, Inc. Automated filling systems and methods
WO2008149345A2 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2009010428A1 (en) 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2010538049A (ja) * 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス 切断型ｇｌｐ−１誘導体及びその治療的使用
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
EP2203458B1 (en) 2007-09-11 2011-11-02 Kyorin Pharmaceutical Co., Ltd. Cyanoaminoquinolones as gsk-3 inhibitors
KR101597841B1 (ko) 2007-09-12 2016-02-26 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 스피로시클릭 아미노퀴놀론
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MX2010005245A (es) 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
RU2510758C2 (ru) 2007-12-31 2014-04-10 Дека Продактс Лимитед Партнершип Инфузионный насосный узел
US8414563B2 (en) 2007-12-31 2013-04-09 Deka Products Limited Partnership Pump assembly with switch
US9456955B2 (en) 2007-12-31 2016-10-04 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US8881774B2 (en) 2007-12-31 2014-11-11 Deka Research & Development Corp. Apparatus, system and method for fluid delivery
US10080704B2 (en) 2007-12-31 2018-09-25 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US12447265B2 (en) 2007-12-31 2025-10-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US8900188B2 (en) 2007-12-31 2014-12-02 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
US10188787B2 (en) 2007-12-31 2019-01-29 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2229407B1 (de) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2229406B1 (de) 2008-01-09 2015-04-22 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
US20110046071A1 (en) * 2008-03-05 2011-02-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
CN101555214B (zh) 2008-04-08 2012-07-11 北京嘉事联博医药科技有限公司 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
EP3881874A1 (en) 2008-09-15 2021-09-22 DEKA Products Limited Partnership Systems and methods for fluid delivery
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
ES2614427T3 (es) 2008-11-07 2017-05-31 The General Hospital Corporation Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
IT1392655B1 (it) 2008-11-20 2012-03-16 Bio Ker S R L Site-specific monoconjugated insulinotropic glp-1 peptides.
CA2744383C (en) 2008-11-21 2017-04-25 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
RU2525393C2 (ru) 2009-01-23 2014-08-10 Ново Нордиск А/С Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение
CN102942626B (zh) * 2009-03-05 2015-11-04 江苏豪森医药集团有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
US8071591B2 (en) 2009-03-11 2011-12-06 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
JP5883382B2 (ja) * 2009-06-05 2016-03-15 ヴェロサイエンス・エルエルシー 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2014265118B2 (en) * 2009-06-05 2016-11-17 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
CN102802657A (zh) * 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
JP5961111B2 (ja) 2009-07-15 2016-08-02 デカ・プロダクツ・リミテッド・パートナーシップ 注入ポンプアセンブリのための装置、システム、および方法
US8614182B2 (en) 2009-07-30 2013-12-24 Jiangsu Hansoh Pharmaceuticals Co., Ltd. GLP-1 analogues and their pharmaceutical salts and uses
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
JP2013506635A (ja) 2009-10-02 2013-02-28 サノフイ 骨疾患を処置するための薬剤を製造するためのｓｇｌｔ−１／ｓｇｌｔ−２阻害剤活性を有する化合物の使用
US20120264685A1 (en) 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2011058083A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
MX2012006634A (es) 2009-12-16 2012-06-21 Novo Nordisk As Derivados de peptidos tipo glucagon 1 de doble acilato.
CA2787178C (en) 2010-01-22 2019-02-12 Deka Products Limited Partnership Method and system for shape-memory alloy wire control
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
KR101813595B1 (ko) 2010-01-22 2017-12-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 장기적 생체 내 효능을 갖는 성장 호르몬
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
WO2011107447A1 (en) 2010-03-01 2011-09-09 Novo Nordisk A/S Preparative rp-hplc method for purifying peptides
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
RU2559320C2 (ru) 2010-03-26 2015-08-10 Ново Нордиск А/С Новые аналоги глюкагона
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AU2011247452B2 (en) 2010-04-27 2016-03-17 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
WO2011136361A1 (ja) 2010-04-30 2011-11-03 株式会社 三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
WO2012062803A1 (en) 2010-11-09 2012-05-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
US20140045754A1 (en) 2011-01-19 2014-02-13 Joern Drustrup Glp-1 compositions
JP2014502985A (ja) 2011-01-19 2014-02-06 ノヴォ ノルディスク アー／エス Ｇｌｐ−１粒子および組成物
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US20140031278A1 (en) 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2707713A2 (en) 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
HRP20151068T1 (hr) 2011-08-29 2016-01-01 Sanofi-Aventis Deutschland Gmbh Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013029279A1 (zh) * 2011-09-03 2013-03-07 深圳市健元医药科技有限公司 新的glp-ⅰ类似物及其制备方法和用途
WO2013037690A1 (en) 2011-09-06 2013-03-21 Novo Nordisk A/S Glp-1 derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PL2763690T3 (pl) 2011-10-04 2016-04-29 Sanofi Aventis Deutschland Liksysenatyd do stosowania w leczeniu stenozy i/lub niedrożności w układzie przewodów trzustkowych
WO2013050378A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
MX2014005351A (es) 2011-11-03 2014-05-28 Zealand Pharma As Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
US20150038417A1 (en) 2011-12-09 2015-02-05 Novo Nordisk A/S GLP-1 Agonists
CN104011064A (zh) 2011-12-29 2014-08-27 诺沃—诺迪斯克有限公司 包含非成蛋白质性的氨基酸的二肽
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
LT2814842T (lt) 2012-02-15 2018-11-12 Novo Nordisk A/S Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
RS56593B1 (sr) 2012-02-15 2018-02-28 Novo Nordisk As Antitela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloidnim ćelijama-1 (trem-1)
WO2013134519A2 (en) 2012-03-07 2013-09-12 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
ES2629735T3 (es) * 2012-05-08 2017-08-14 Novo Nordisk A/S Derivados de GLP-1 doblemente acilados
EP2664374A1 (en) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Lysin-glutamic acid dipeptide derivatives
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
PL2866825T3 (pl) 2012-07-01 2021-02-22 Novo Nordisk A/S <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
IN2015DN00544A (pt) 2012-07-23 2015-06-26 Zealand Pharma As
FR2994848B1 (fr) 2012-08-30 2014-08-22 Univ Paris Curie Traitement de l'arthrose par les hormones incretines ou leurs analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US20150273069A1 (en) 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN103059127B (zh) * 2013-01-07 2014-12-17 天津嘉宏科技有限公司 Glp-1类似物及其制备方法与应用
CA2901439C (en) 2013-03-01 2023-04-04 Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
PT2968443T (pt) 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
RU2671406C2 (ru) 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
WO2015003145A1 (en) 2013-07-03 2015-01-08 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
ES2688708T3 (es) 2013-10-17 2018-11-06 Zealand Pharma A/S Análogos de glucagón acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN106061940A (zh) 2013-11-05 2016-10-26 本古里安大学内盖夫研究发展局 治疗糖尿病和由其引发的并发疾病的化合物
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
CN103884846B (zh) * 2014-03-06 2016-06-08 杭州九源基因工程有限公司 一种利拉鲁肽生物学活性的检测方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
CN106132985B (zh) * 2014-04-07 2020-10-13 诺和诺德股份有限公司 双酰化glp-1化合物
HRP20200763T1 (hr) * 2014-05-07 2020-07-24 Novo Nordisk A/S Liječenje dijabetesa tip 1 uz pomoć glp-1 i protutijela protiv il-21
US10105442B2 (en) 2014-05-07 2018-10-23 Novo Nordisk A/S Treatment of diabetes type 1 using GLP-1 and anti-IL-21
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104987383A (zh) * 2014-07-08 2015-10-21 四川百利药业有限责任公司 一种glp-1衍生物
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
BR112017001010A2 (pt) 2014-07-17 2017-11-14 Protagonist Therapeutics Inc inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais
TN2017000008A1 (en) 2014-07-17 2018-07-04 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
ES2685987T3 (es) 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
JP6730278B2 (ja) * 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
DK3236991T3 (da) 2014-12-23 2019-08-26 Novo Nordisk As Fgf21-derivater og anvendelser deraf
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3405476B1 (en) 2016-01-20 2022-05-18 Polypeptide Laboratories Holding (PPL) AB METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
EP3205660A1 (en) 2016-02-10 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of peptides with pswang linker
EP3196206A1 (en) 2016-01-20 2017-07-26 Lonza Ltd Method for preparation of liraglutide
EP3205664A1 (en) 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of liraglutide using bal linker
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
MA43684A (fr) 2016-03-04 2018-11-28 Novo Nordisk As Liraglutide utilisé dans le traitement de maladies rénales
WO2017149109A1 (en) 2016-03-04 2017-09-08 Novo Nordisk A/S Liraglutide in diabetic foot ulcer
JP6991196B2 (ja) 2016-03-23 2022-02-03 バッヘン・ホールディング・アクチエンゲゼルシャフト グルカゴン様ペプチドを製造するための方法
WO2017162653A1 (en) 2016-03-23 2017-09-28 Bachem Holding Ag Purification of glucagon-like peptide 1 analogs
CN115925790A (zh) 2016-03-23 2023-04-07 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
US20190224122A1 (en) 2016-09-23 2019-07-25 Delpor, Inc. Stable compositions for incretin mimetic compounds
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EP3544682A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
JP7193455B2 (ja) 2016-11-28 2022-12-20 ノヴォ ノルディスク アー／エス 心血管状態におけるインスリンデグルデク
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
US11130793B2 (en) 2016-12-09 2021-09-28 Zealand Pharma A/S GLP-1/GLP-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
SG11201903938XA (en) 2016-12-09 2019-05-30 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
GB201621987D0 (en) 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
MA49883A (fr) 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
WO2018210919A1 (en) 2017-05-17 2018-11-22 Novo Nordisk A/S Glp-1 compositions and uses thereof
EP4361173A3 (en) 2017-05-31 2024-07-03 University of Copenhagen Long-acting gip peptide analogues
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
EP3681529A1 (en) 2017-09-10 2020-07-22 Novo Nordisk A/S Mic-1 and glp-1 for use in the treatment of obesity
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
JP2021514936A (ja) 2017-12-19 2021-06-17 ノヴォ ノルディスク アー／エス Ｇｌｐ−１ペプチドの可溶性
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3091993A1 (en) 2018-02-27 2019-09-06 Zp Spv 3 K/S Compstatin analogues and their medical uses
AR117566A1 (es) 2018-04-02 2021-08-18 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y sus usos
ES2925678T3 (es) 2018-04-05 2022-10-19 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
US11523972B2 (en) 2018-04-24 2022-12-13 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
TW201946930A (zh) * 2018-05-15 2019-12-16 展旺生命科技股份有限公司 製備利拉魯肽衍生物的方法
US10905738B2 (en) 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
CA3121043A1 (en) 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues
EP3938037A1 (en) 2019-03-15 2022-01-19 Diet4Life ApS Combination of dietary peptides
CN113677702B (zh) 2019-04-01 2025-06-13 诺和诺德股份有限公司 针对利拉鲁肽的抗体及其用途
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
US20220306695A1 (en) 2019-08-27 2022-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
BR112022003999A2 (pt) 2019-09-03 2022-05-31 Protagonist Therapeutics Inc Miméticos de hepcidina conjugados
CN114728042A (zh) 2019-11-06 2022-07-08 诺和诺德股份有限公司 用于痴呆的glp-1受体激动剂
JP2023502004A (ja) 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
WO2021105393A1 (en) 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
CN111040022B (zh) 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
JP2023510218A (ja) 2019-12-30 2023-03-13 ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド 長時間作用型ｇｌｐ－１化合物
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
CR20220332A (es) 2020-01-15 2022-11-28 Janssen Biotech Inc Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
EP4126003A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JP7777085B2 (ja) 2020-04-29 2025-11-27 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
CN115515594A (zh) 2020-05-07 2022-12-23 腓特烈斯贝医院 高尿酸血症的治疗
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
JP2025505052A (ja) 2021-01-24 2025-02-20 デイヴィッド フォレスト マイケル Ａｔｐ合成酵素の阻害剤－美容および治療への使用
FR3120189B1 (fr) 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
CN113025675B (zh) * 2021-05-21 2021-08-20 凯莱英医药集团（天津）股份有限公司 多肽的制备方法
WO2023285347A1 (en) 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
PE20240595A1 (es) 2021-07-14 2024-03-21 Janssen Biotech Inc Inhibidores peptidicos lipidicos del receptor de iinterleucina-23
CN116635402B (zh) 2021-07-14 2024-03-15 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
EP4392054A1 (en) 2021-09-03 2024-07-03 Zealand Pharma A/S Dosage regime
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
JP2025511189A (ja) * 2022-03-28 2025-04-15 ブリストル－マイヤーズ スクイブ カンパニー 大環状免疫調節剤
KR20240163717A (ko) 2022-03-30 2024-11-19 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법
AU2023346836A1 (en) 2022-09-19 2025-03-20 Zealand Pharma A/S Combination therapy
EP4593864A1 (en) 2022-09-28 2025-08-06 Zealand Pharma A/S Methods for treating obesity
EP4345104B1 (en) 2022-09-30 2024-08-28 Bachem Holding AG Method for preparing liraglutide
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
AU2023415591A1 (en) 2022-12-30 2025-08-14 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN121285571A (zh) 2023-06-09 2026-01-06 太阳医药工业有限公司 Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
KR20240176455A (ko) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 시클로덱스트린을 포함하는 약학적 제형
TW202515598A (zh) 2023-06-21 2025-04-16 丹麥商西蘭製藥公司 具有增進性能之類似物
TW202504913A (zh) 2023-06-21 2025-02-01 丹麥商西蘭製藥公司 減重
CN121443305A (zh) 2023-06-30 2026-01-30 西兰制药公司 组合治疗
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025122721A1 (en) * 2023-12-05 2025-06-12 Shattuck Labs, Inc. Chimeric proteins and uses thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) * 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
WO1987006941A1 (en) 1986-05-05 1987-11-19 The General Hospital Corporation Insulinotropic hormone
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
EP0658568A1 (en) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK144093D0 (pt) * 1993-12-23 1993-12-23 Novo Nordisk As
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE278772T1 (de) * 1994-10-21 2004-10-15 Nutrinova Gmbh Verfahren zur kultivierung lipidabhängiger tetrahymeniden und ein verfahren zur herstellung von biogenen wertstoffen aus lipidabhängigen tetrahymeniden
KR100556067B1 (ko) * 1996-08-30 2006-03-07 노보 노르디스크 에이/에스 지엘피 - 1 유도체

Also Published As

Publication number Publication date
JP3149958B2 (ja) 2001-03-26
AU732957B2 (en) 2001-05-03
BRPI9711437B1 (pt) 2017-05-16
BR9711437A (pt) 2000-01-18
CZ300837B6 (cs) 2009-08-26
ATE356830T1 (de) 2007-04-15
NO990950D0 (no) 1999-02-26
EP0944648B1 (en) 2007-03-14
FR09C0054I2 (fr) 2011-04-01
HU227021B1 (en) 2010-05-28
NO2019036I1 (no) 2019-09-20
NL300422I1 (nl) 2010-01-04
JP2000500505A (ja) 2000-01-18
EP1826216A1 (en) 2007-08-29
IL128332A0 (en) 2000-01-31
KR20000035964A (ko) 2000-06-26
IL128332A (en) 2008-04-13
NO2009027I1 (no) 2009-11-30
FR09C0054I1 (pt) 2009-04-12
DE122009000079I1 (de) 2010-05-27
NO325273B1 (no) 2008-03-17
PT944648E (pt) 2007-06-26
DE69737479T4 (de) 2010-05-06
HUP9903714A2 (hu) 2000-03-28
DE69737479D1 (de) 2007-04-26
DE69737479T2 (de) 2007-11-29
PL331896A1 (en) 1999-08-16
JP2001011095A (ja) 2001-01-16
IL189136A (en) 2015-05-31
PL192359B1 (pl) 2006-10-31
KR100556067B1 (ko) 2006-03-07
CA2264243C (en) 2004-10-05
CN1271086C (zh) 2006-08-23
DK0944648T3 (da) 2007-07-02
EP0944648A1 (en) 1999-09-29
NO2009027I2 (no) 2015-01-19
CZ62999A3 (cs) 1999-07-14
WO1998008871A1 (en) 1998-03-05
ES2283025T3 (es) 2007-10-16
CA2264243A1 (en) 1998-03-05
RU2214419C2 (ru) 2003-10-20
IL189136A0 (en) 2008-06-05
CA2468374A1 (en) 1998-03-05
CN1232470A (zh) 1999-10-20
UA72181C2 (uk) 2005-02-15
NL300422I2 (nl) 2010-04-01
JP2006348038A (ja) 2006-12-28
AU3847897A (en) 1998-03-19
HUP9903714A3 (en) 2000-07-28
NO990950L (no) 1999-04-28
AU732957C (en) 1998-03-19
CA2468374C (en) 2010-12-21
DE122009000079I2 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
BRPI9711437B8 (pt) derivados de glp-1
BR9806484A (pt) Método e aparelho para processamento de chamada com tolerância de falha
ECSP930945A (es) Metodo para la preparacion derivados carboximetilados
BR0201817B1 (pt) dispositivo expansÍvel para uso em um poÇo, e mÉtodo de expansço de um dispositivo de poÇo em um poÇo.
ES2189342T3 (es) Componente tibial de una protesis de rodilla.
EE04019B1 (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
FI101732B1 (fi) Avainaihio, avain ja lukko- ja avainyhdistelmä
ITMI931717A0 (it) Derivati (di)azacicloesanici e diazacicloeptanici
ITMI951367A0 (it) Derivati della colchicina loro uso e formulazioni che li contengono
DE58909335D1 (de) Hochdruck-Entladungslampe, insbesondere Hochdrucknatriumdampflampe.
IT1237479B (it) Derivati della capsaicina, loro preparazione e loro impiego come medicamenti (caso 700-0062)
ITMI911520A0 (it) Derivati di piperidina, loro preparazione e uso
NL191529C (nl) Inklapbaar zit- en ligmeubel.
NO894594D0 (no) Farmasoeytiske sammensetninger omfattende labdan diterpenoid-derivater og pyrimido(6,1-a)isoquinolin-4-ono-derivater.
ES2033315T3 (es) Derivados de 5-metil-10,11-dihidro-5h-dibenzo(a,d)ciclohepten-5,10-imina.
FI941214A7 (fi) Bentsimidatsolin johdannaisia, niiden valmistus ja käyttö
ES1023616Y (es) Estructura plegable perfeccionada, para sillas de minusvalidos y similares.
ITMI940356A0 (it) Derivati della purina ad attivita&#39; farmacologica loro uso e composizioni farmaceutiche che li contengono
IT8819333A0 (it) 1,1 difluoroallil e 1,1difluoropropargil derivati.
ATA210591A (de) Verriegelung für türen, insbesondere drehfalttüren
IT8819080A0 (it) Derivati diidropiridinici, loro preparazione e impieghi farmaceutici.
ITRM930474A0 (it) Eritrociti incorporanti alcool ossidasi e loro uso nella detossificazione da metanolo.
AR243352A1 (es) Mejoras en estructuras plegables, componentes de sillas, sillones, reposeras y otros asientos.
BR9802431B1 (pt) composição parasiticida compreendendo ivermectina em associação com levamisol, processo para sua preparação, e uso da referida composição.
FI891351A0 (fi) Bytesmekanism foer radioaktiva prov som maets separat i en gammaraeknare.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: EM RESPOSTA AO CUMPRIMENTO DE EXIGENCIA QUE FOI NOTIFICADO ATRAVES DA RPI 1760, DE 28/09/2004 REFERENTE AO EXAME TECNICO DE QUADRO REIVINDICATORIO COMPREENDIDO DE 48 REIVINDICACOES, A REQUERENTE SUBMETEU UM NOVO QUADRO REINVINDICATORIO COMPREEMDIDO DE 49 REINVINDICACOES PETICAO NO 020040018874, DE 22/12/2004, SEM QUE TENHA SIDO FEITA A DEVIDA RETRIBUICAO DA REIVINDICACOO ADICIONAL. O REQUERENTE DEVERA SANAR TAL IRREGULARIDA COMPREMENTANDO A TAXA RELATIVA A 01 REIVINDICACAO EXCEDENTE.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37 E 25 DA LPI 9.279

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/08/1997 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/08/2017

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.001713/2022-85 ORIGEM: 9A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1088573-79.2021.4.01.3400 ACAO DE PROCEDIMENTO COMUM AUTOR: NOVO NORDISK A/S E NOVO NORDISK FARMACEUTICA DO BRASIL LTDA. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.001713/2022-85 SECAO JUDICIARIA DO DISTRITO FEDERAL 9A VARA FEDERAL CIVEL DA SJDF PROCESSO: 1088573-79.2021.4.01. AUTOR: NOVO NORDISK FARMACEUTICA DO BRASIL LTDA E OUTROS REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI- SENTENCA: ANTE O EXPOSTO, JULGO IMPROCEDENTES OS PEDIDOS E EXTINGO O PROCESSO, COM RESOLUCAO DE MERITO, COM BASE NO ART. 487, INCISO I, DO CPC. TRANSITO EM JULGADO.